

BioFishency Significantly Increases Sales in 2018

The Company will license new aquaculture technology for cold water applications.

Misgav, Israel – 16 April 2018 – [BioFishency Ltd. \(“BioFishency”\)](#), a portfolio company of [The Trendlines Group \(SGX: 42T; OTCQX: TRNLY\)](#), announced that it has completed sales of approximately US\$800,000 so far in 2018. In just three months the company has increased its sales by a 44% increase compared to sales for all of 2017.

BioFishency projects at least another US\$1 million in sales by the end of this year. The increase is due to expansion into multiple countries and growth in areas where the Company already has successfully operating systems, including Israel, China, Bangladesh, India, Congo, and Indonesia.

As the world’s population looks to increase the production of protein to meet the growing demand, fish provides a significant solution. However, the pressure on water and land resources make growth in the aquaculture market challenging.

BioFishency’s all-in-one water treatment systems for land-based aquaculture overcome limitations of water availability and increase fish yields.

The BioFishency Mini RAS (Recirculating Aquaculture System) makes water treatment available in aquaculture ventures that use fresh, brackish or seawater in the ponds. The Mini RAS overcomes two main obstacles in commercial fish growing: limited water availability and toxic ammonia accumulation (from fish waste). The plug-and-play system has demonstrated a reduction in water consumption by up to 85% while increasing yields by approximately 2.5 times.

Further plans for 2018 include BioFishency’s licensing of a new technology from [The Technion Research & Development Foundation Ltd.](#) to develop an additional product line. BioFishency’s current product families are for all types of warm water aquaculture systems. The technology to be developed will suit cold water applications, extending BioFishency’s product lines to all sectors of the land-based aquaculture market.

According to BioFishency CTO Igal Magen, “BioFishency’s system leverages the potential growth of aquaculture production and has the potential to close the ‘technology gap’ for many fish farmers. We are excited about developing a new product line and looking forward to a very successful year ahead. We welcome partnerships with strategics or investors who want to be a part of the global food solution.”

About The Trendlines Group

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

This press release has been prepared by The Trendlines Group Ltd. (the "Company") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Senior Manager, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg)

Contact

Israel

Shira Zimmerman, The Trendlines Group

shira@trendlines.com

Tel: +972.72.260.7000

Singapore

Reyna MEI, Financial PR

reyna@financialpr.com.sg

Tel: +65.6438.2990